Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...
Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to ...
President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to ...
Tubulis GmbH has sealed a potential $415 million option and licensing deal under which it will apply proprietary technologies to discover an antibody-drug conjugate (ADC) against a solid tumor target ...
During a busy day of dealmaking, Cour Pharmaceuticals entered a pact with Roche Holding AG’s Genentech unit to advance tolerogenic nanoparticle treatments for an autoimmune disease indication, ...
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...